350 related articles for article (PubMed ID: 20660842)
1. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.
Lang S; Mary-Krause M; Cotte L; Gilquin J; Partisani M; Simon A; Boccara F; Costagliola D;
Arch Intern Med; 2010 Jul; 170(14):1228-38. PubMed ID: 20660842
[TBL] [Abstract][Full Text] [Related]
2. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.
Worm SW; Sabin C; Weber R; Reiss P; El-Sadr W; Dabis F; De Wit S; Law M; Monforte AD; Friis-Møller N; Kirk O; Fontas E; Weller I; Phillips A; Lundgren J
J Infect Dis; 2010 Feb; 201(3):318-30. PubMed ID: 20039804
[TBL] [Abstract][Full Text] [Related]
3. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.
Obel N; Farkas DK; Kronborg G; Larsen CS; Pedersen G; Riis A; Pedersen C; Gerstoft J; Sørensen HT
HIV Med; 2010 Feb; 11(2):130-6. PubMed ID: 19682101
[TBL] [Abstract][Full Text] [Related]
4. Influence of control selection in nested case-control studies: the example of exposure to antiretroviral treatment (ART) and the risk of myocardial infarction (MI) in the French Hospital Database on HIV (FHDH-ANRS CO4).
Guiguet M; Mary-Krause M; Ename B; Costagliola D; Grabar S
Pharmacoepidemiol Drug Saf; 2008 May; 17(5):468-74. PubMed ID: 18324608
[TBL] [Abstract][Full Text] [Related]
5. Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1-infected adult subjects.
Carosi ; Lazzarin ; Stellbrink ; Moyle ; Rugina ; Staszewski ; Givens ; Ross ; Granier ; Ait-Khaled ; Leather ; Nichols
HIV Clin Trials; 2009; 10(6):356-67. PubMed ID: 20133266
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.
Calza L; Manfredi R; Pocaterra D; Chiodo F
Int J STD AIDS; 2008 Aug; 19(8):541-4. PubMed ID: 18663041
[TBL] [Abstract][Full Text] [Related]
7. Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.
Merchante N; López-Cortés LF; Delgado-Fernández M; Ríos-Villegas MJ; Márquez-Solero M; Merino D; Pasquau J; García-Figueras C; Martínez-Pérez MA; Omar M; Rivero A; Macías J; Mata R; Pineda JA;
AIDS Patient Care STDS; 2011 Jul; 25(7):395-402. PubMed ID: 21688986
[TBL] [Abstract][Full Text] [Related]
8. HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals.
Lang S; Mary-Krause M; Simon A; Partisani M; Gilquin J; Cotte L; Boccara F; Costagliola D;
Clin Infect Dis; 2012 Aug; 55(4):600-7. PubMed ID: 22610928
[TBL] [Abstract][Full Text] [Related]
9. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
[TBL] [Abstract][Full Text] [Related]
10. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.
Bedimo RJ; Westfall AO; Drechsler H; Vidiella G; Tebas P
Clin Infect Dis; 2011 Jul; 53(1):84-91. PubMed ID: 21653308
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of myocardial infarction and coronary artery disease in subjects taking lopinavir/ritonavir: a study using clinical trial and pharmacovigilance databases.
Da Silva B; Tschampa J; Beron J; Fredrick L; Patwardhan M; Zachry W; Woodward WC; Norton M; Nilius A
Int J Clin Pharmacol Ther; 2012 Jun; 50(6):391-402. PubMed ID: 22541744
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
Bongiovanni M; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Bini T; Monforte Ad
Int J Antimicrob Agents; 2005 Jul; 26(1):88-91. PubMed ID: 15878262
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.
Fortuny C; Duiculescu D; Cheng K; Garges HP; Cotton M; Tamarirt DP; Ford SL; Wire MB; Givens N; Ross LL; Lou Y; Perger T; Sievers J
Pediatr Infect Dis J; 2014 Jan; 33(1):50-6. PubMed ID: 23811744
[TBL] [Abstract][Full Text] [Related]
14. Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV.
Costagliola D; Potard V; Lang S; de Castro N; Cotte L; Duval X; Duvivier C; Grabar S; Mary-Krause M; Partisani M; Ronot-Bregigeon S; Simon A; Tattevin P; Weiss L; Zucman D; Katlama C; Raffi F; Boccara F
J Infect Dis; 2020 Feb; 221(4):516-522. PubMed ID: 31828320
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study.
Blick G; Greiger-Zanlungo P; Gretz S; Han J; Dupree D; Garton T; Yau LH; Wine BC; Pakes GE;
Int J STD AIDS; 2012 Mar; 23(3):e18-22. PubMed ID: 22581890
[TBL] [Abstract][Full Text] [Related]
16. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.
Taburet AM; Raguin G; Le Tiec C; Droz C; Barrail A; Vincent I; Morand-Joubert L; Chêne G; Clavel F; Girard PM
Clin Pharmacol Ther; 2004 Apr; 75(4):310-23. PubMed ID: 15060509
[TBL] [Abstract][Full Text] [Related]
17. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?
Sibiude J; Warszawski J; Tubiana R; Dollfus C; Faye A; Rouzioux C; Teglas JP; Ekoukou D; Blanche S; Mandelbrot L
Clin Infect Dis; 2012 May; 54(9):1348-60. PubMed ID: 22460969
[TBL] [Abstract][Full Text] [Related]
18. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
[TBL] [Abstract][Full Text] [Related]
19. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events.
Monforte Ad; Reiss P; Ryom L; El-Sadr W; Dabis F; De Wit S; Worm SW; Law MG; Weber R; Kirk O; Pradier C; Phillips AN; Lundgren JD; Sabin CA
AIDS; 2013 Jan; 27(3):407-15. PubMed ID: 23291539
[TBL] [Abstract][Full Text] [Related]
20. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.
Cruciani M; Zanichelli V; Serpelloni G; Bosco O; Malena M; Mazzi R; Mengoli C; Parisi SG; Moyle G
AIDS; 2011 Oct; 25(16):1993-2004. PubMed ID: 21716077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
